Pharma Giant Daiichi Sankyo Delays Earnings, Stock Tanks 4%—Is This a Red Flag or Buy Signal?

Pharma Giant Daiichi Sankyo Delays Earnings, Stock Tanks 4%—Is This a Red Flag or Buy Signal?

Sunao Manabe, Daiichi Sankyo's CFO, woke up Friday to deliver the news no executive wants: the company's full-year results, due today, are postponed. No reason given in the initial statement—just a vague promise of "later disclosure." Shares in the Japanese drugmaker, known for its Enhertu cancer drug that's raked in over $3 billion in sales last year alone, opened down 4% at 5,800 yen.

Investors hate uncertainty more than bad news. Daiichi's been a biotech darling, with its antibody-drug conjugates treating breast and lung cancers pushing revenue up 20% in recent quarters. But this delay echoes past scandals—like when peers like Takeda faced accounting probes. Tokyo traders dumped shares fast: volume spiked 3x normal, wiping out ¥150 billion in market cap by 9 AM. Compare that to stable pharma peers like Astellas, up 1% today—Daiichi's now trading at a 15% discount to its 52-week high.

The punch line? Postponements like this have led to 10% average drops over the next month in similar cases—unless it's just paperwork.

Gobble's Take: If you're hunting pharma dips, watch for the rescheduled date—this could be your sub-$6,000 yen entry before the rebound.

Source: Endpoints News

Mondi Q1 EBITDA Flatlines at €400M—Stock Dips 2%, But Packaging Demand Hints at Turnaround

CEO Andrew King kicked off Mondi's earnings call admitting the obvious: Q1 EBITDA held flat at €400 million, matching last year despite pulp prices crashing 15%. The London-listed packaging giant, which wraps everything from Amazon boxes to coffee pouches, blamed weak European demand—industrial output down 2% across the continent.

Dig deeper, and contrasts emerge. While volumes dipped 1%, pricing held firm, and hygiene products (think diaper wraps) grew 5%. Mondi's now betting big on recycled materials: 70% of output sustainable, versus rivals at 50%. Shares slipped 2% to £1.40 in early London trade, but that's peanuts compared to the 20% rally since January. Analysts whisper buy: forward P/E at 8x earnings, half the sector average.

The real kicker? Flat EBITDA in a recession means resilience—packaging is recession-proof, as e-commerce boomed 12% last quarter.

Gobble's Take: Packaging stocks like this scream value if inflation cools—grab shares now for dividend yields north of 4%.

Source: Investing.com

SLM Corp Swings Wild: Down 10% This Week, Now Trading at 9x Earnings—Value Trap or Student Loan Goldmine?

Picture this: SLM Corp's CEO Scott Remley watches his stock yo-yo from $28 to $25 in days, triggered by Fed rate cut whispers. The student lender, rebranded Navient, saw shares swing 10% on no news—just market jitters over $1.7 trillion in U.S. student debt.

Here's the gap: delinquencies are at record lows (3.5%), thanks to Biden-era forgiveness wiping $150 billion off books. SLM's net interest margins hit 5.2%, fattest in years, with Q1 originations up 8%. Yet shares trade at 9x forward earnings—versus banks at 12x. Bears point to election risks; bulls see rate cuts boosting refinancings by 20%.

Swing over: at $25, it's a 15% discount to book value—cheaper than peers like SoFi, down 5% less dramatically.

Gobble's Take: If rates drop 50bps by summer, SLM could rocket 25%—perfect for your IRA if you stomach the volatility.

Source: Yahoo Finance

In Case You Missed It

Yesterday's top stories:

• Burry Bets on Lululemon While the Market Bails — "Patience Trade" or Catching a Falling Knife?
• Tower Semiconductor Beats Q4 EPS by 12% — Then Drops Anyway
• Betolar Posts Record Revenue. Shares Fall Anyway. Welcome to Green Tech Investing.
• H&M Is Up 27% in a Year. At 18x Earnings, Is the Comeback Already Priced In?